(Reuters) -Corcept Therapeutics said on Monday its experimental combination ovarian cancer drug improved survival in patients with a type of ovarian cancer without the disease getting worse in a late-stage trial, sending the company’s shares up 80%.
The drug, relacorilant, in combination with chemotherapy showed a 30% reduction in disease-progression risk in platinum-resistant ovarian cancer patients, compared to those treated with chemotherapy alone.
Platinum-resistant ovarian cancer is a type of cancer that no longer responds to platinum-based chemotherapy treatments, which are typically used as a first-line therapy.
Corcept’s shares were trading at $100 before the bell.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shounak Dasgupta)
